​

Immunovant (IMVT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

IMVT Stock Forecast

Immunovant stock forecast is as follows: an average price target of $51.00 (represents a 98.75% upside from IMVT’s last price of $25.66) and a rating consensus of 'Buy', based on 22 wall street analysts offering a 1-year stock forecast.

IMVT Price Target

The average price target for Immunovant (IMVT) is $51.00 based on 1-year price targets from 22 Wall Street analysts in the past 3 months, with a price target range of $51.00 to $51.00. This represents a potential 98.75% upside from IMVT's last price of $25.66.

IMVT Analyst Ratings

Buy

According to 22 Wall Street analysts, Immunovant's rating consensus is 'Buy'. The analyst rating breakdown for IMVT stock is 0 'Strong Buy' (0.00%), 16 'Buy' (72.73%), 4 'Hold' (18.18%), 2 'Sell' (9.09%), and 0 'Strong Sell' (0.00%).

Immunovant Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 10, 2024Douglas TsaoH.C. Wainwright$51.00$30.2068.87%98.75%
Jun 03, 2024Leland GershellOppenheimer$46.00$25.3981.17%79.27%
May 30, 2024Yatin SunejaGuggenheim$48.00$26.4181.75%87.06%
May 30, 2024Yasmeen RahimiPiper Sandler$57.00$27.83104.81%122.14%
Mar 13, 2024Corinne JohnsonGoldman Sachs$50.00$31.8257.13%94.86%
Sep 26, 2022Colin BristowUBS$5.00$4.882.46%-80.51%

The latest Immunovant stock forecast, released on Sep 10, 2024 by Douglas Tsao from H.C. Wainwright, set a price target of $51.00, which represents a 68.87% increase from the stock price at the time of the forecast ($30.20), and a 98.75% increase from IMVT last price ($25.66).

Immunovant Price Target by Period

1M3M12M
# Anlaysts--5
Avg Price Target--$50.40
Last Closing Price$25.66$25.66$25.66
Upside/Downside-100.00%-100.00%96.41%

In the current month, the average price target of Immunovant stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Immunovant's last price of $25.66. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 09, 2024OppenheimerOutperformOutperformHold
Sep 25, 2024Goldman SachsBuyBuyHold
Sep 12, 2024Piper SandlerOverweightOverweightHold
Sep 10, 2024H.C. WainwrightBuyBuyHold
Sep 09, 2024CitigroupBuyBuyHold
Jun 03, 2024OppenheimerOutperformOutperformHold
May 31, 2024Wells FargoOverweightOverweightHold
May 30, 2024GuggenheimBuyBuyHold
May 30, 2024Piper SandlerOverweightOverweightHold
May 29, 2024Goldman SachsNeutralNeutralHold
Dec 21, 2023Deutsche BankBuyBuyHold
Oct 13, 2023UBSNeutralBuyUpgrade
Sep 26, 2023Raymond JamesOutperformUpgrade
Feb 15, 2023Cantor FitzgeraldOverweightInitialise
Feb 13, 2023BNP ParibasNeutralDowngrade
Feb 13, 2023BarclaysUnderweightDowngrade
Feb 13, 2023BenchmarkBuyUpgrade
Feb 13, 2023Credit SuisseOutperformUpgrade
Feb 13, 2023Deutsche BankHoldUpgrade
Feb 13, 2023Evercore ISIOutperformUpgrade
Feb 13, 2023Piper SandlerNeutralDowngrade
Feb 13, 2023RBC CapitalOutperformUpgrade
Feb 13, 2023BernsteinBuyUpgrade
Feb 13, 2023Roth CapitalNeutralDowngrade
Feb 13, 2023ScotiabankPerformDowngrade
Feb 13, 2023Wolfe ResearchPeer PerformDowngrade
Feb 13, 2023NeedhamHoldDowngrade
Feb 13, 2023Morgan StanleyUnderweightDowngrade
Feb 13, 2023Exane BNP ParibasNeutralDowngrade
Feb 13, 2023GuggenheimBuyUpgrade
Jan 03, 2023Wells FargoOverweightUpgrade
Sep 26, 2022UBSNeutralDowngrade

Immunovant's last stock rating was published by Oppenheimer on Oct 09, 2024. The company gave IMVT a "Outperform" rating, the same as its previous rate.

Immunovant Financial Forecast

Immunovant Revenue Forecast

Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue--------
Avg Forecast--------
High Forecast--------
Low Forecast--------
# Analysts--------
Surprise %--------

Immunovant's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. IMVT's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Immunovant EBITDA Forecast

Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts--------
EBITDA--------
Avg Forecast--------
High Forecast--------
Low Forecast--------
Surprise %--------

undefined analysts predict IMVT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Immunovant's previous annual EBITDA (undefined) of $NaN.

Immunovant Net Income Forecast

Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts--------
Net Income--------
Avg Forecast$-123.03M$-118.84M$-119.13M$-114.25M$-106.90M$-107.04M$-86.24M$-76.54M
High Forecast$-123.03M$-118.84M$-119.13M$-114.25M$-80.90M$-83.26M$-86.24M$-76.54M
Low Forecast$-123.03M$-118.84M$-119.13M$-114.25M$-118.46M$-118.94M$-86.24M$-76.54M
Surprise %--------

Immunovant's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IMVT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Immunovant SG&A Forecast

Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts--------
SG&A--------
Avg Forecast--------
High Forecast--------
Low Forecast--------
Surprise %--------

Immunovant's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to IMVT last annual SG&A of $NaN (undefined).

Immunovant EPS Forecast

Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts--------
EPS--------
Avg Forecast$-0.84$-0.81$-0.81$-0.78$-0.73$-0.73$-0.59$-0.52
High Forecast$-0.84$-0.81$-0.81$-0.78$-0.55$-0.57$-0.59$-0.52
Low Forecast$-0.84$-0.81$-0.81$-0.78$-0.81$-0.81$-0.59$-0.52
Surprise %--------

According to undefined Wall Street analysts, Immunovant's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IMVT previous annual EPS of $NaN (undefined).

Immunovant Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
LEGNLegend Biotech$34.68$89.60158.36%Buy
PLRXPliant Therapeutics$14.37$35.50147.04%Buy
ABUSArbutus Biopharma$3.46$8.50145.66%Buy
STOKStoke Therapeutics$12.10$26.50119.01%Buy
ARQTArcutis Biotherapeutics$14.86$31.00108.61%Buy
APLSApellis Pharmaceuticals$34.53$70.80105.04%Buy
AMLXAmylyx Pharmaceuticals$4.28$8.2592.76%Buy
DAWNDay One Biopharmaceuticals$12.64$24.0089.87%Buy
IMVTImmunovant$27.91$51.0082.73%Buy
AKROAkero Therapeutics$30.61$50.0063.35%Buy
ETNB89bio$7.98$12.0050.38%Buy
PTGXProtagonist Therapeutics$40.69$57.3340.89%Buy
ACLXArcellx$82.03$111.6036.05%Buy
BPMCBlueprint Medicines$96.48$122.6027.07%Buy
MDGLMadrigal Pharmaceuticals$306.08$315.753.16%Buy

IMVT Forecast FAQ

Is Immunovant a good buy?

Yes, according to 22 Wall Street analysts, Immunovant (IMVT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 16 'Buy' recommendations, accounting for 72.73% of IMVT's total ratings.

What is IMVT's price target?

Immunovant (IMVT) average price target is $51 with a range of $51 to $51, implying a 98.75% from its last price of $25.66. The data is based on 22 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Immunovant stock go up soon?

According to Wall Street analysts' prediction for IMVT stock, the company can go up by 98.75% (from the last price of $25.66 to the average price target of $51), up by 98.75% based on the highest stock price target, and up by 98.75% based on the lowest stock price target.

Can Immunovant stock reach $40?

IMVT's average twelve months analyst stock price target of $51 supports the claim that Immunovant can reach $40 in the near future.

What are Immunovant's analysts' financial forecasts?

Immunovant's analysts financial forecasts for the fiscal year (Mar 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-377M (high $-327M, low $-400M), average SG&A $0 (high $0, low $0), and average EPS is $-2.573 (high $-2.233, low $-2.734). IMVT's analysts financial forecasts for the fiscal year (Mar 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-475M (high $-475M, low $-475M), average SG&A $0 (high $0, low $0), and average EPS is $-3.245 (high $-3.245, low $-3.245).